Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus placebo in idiopathic edema
IRCT20230314057712N1Phase 4Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in idiopathic edema comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Amount of edema. Started Apr 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
idiopathic edema
Beyond the preview
Go deeper on IRCT20230314057712N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230314057712N1.